The Juvenile Arthritis drugs in development market research report provides comprehensive information on the therapeutics under development for Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Juvenile Arthritis. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Juvenile Arthritis - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Juvenile Arthritis and features dormant and discontinued products.

GlobalData tracks 43 drugs in development for Juvenile Arthritis by 36 companies/universities/institutes. The top development phase for Juvenile Arthritis is preclinical with 11 drugs in that stage. The Juvenile Arthritis pipeline has 40 drugs in development by companies and three by universities/ institutes. Some of the companies in the Juvenile Arthritis pipeline products market are: Shilpa Biologicals, Swedish Orphan Biovitrum and Mycenax Biotech.

The key targets in the Juvenile Arthritis pipeline products market include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF), Interleukin 6 Receptor Subunit Alpha (IL6R1 or Membrane Glycoprotein 80 or CD126 or IL6R), and Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

The key mechanisms of action in the Juvenile Arthritis pipeline product include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor with 14 drugs in Pre-Registration. The Juvenile Arthritis pipeline products include ten routes of administration with the top ROA being Subcutaneous and six key molecule types in the Juvenile Arthritis pipeline products market including Monoclonal Antibody, and Small Molecule.

Juvenile Arthritis overview

Juvenile arthritis (JA), also known as pediatric rheumatic disease, encompasses a group of inflammatory conditions affecting children and adolescents under the age of 16. This condition causes chronic joint inflammation, leading to stiffness, pain, swelling, and potential damage to joints and other tissues. Diagnosis of juvenile arthritis involves a comprehensive evaluation by a pediatric rheumatologist. It includes a physical examination, assessment of symptoms, blood tests, imaging studies (X-rays, ultrasound, MRI), and sometimes joint fluid analysis to rule out other conditions and confirm the diagnosis.

For a complete picture of Juvenile Arthritis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.